New approaches to the treatment of myelodysplasia

Oncologist

Volumn 7, Issue SUPPL. 1, 2002, Pages 39-49

  List, Alan F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute myeloid leukemia; Investigational agents; Myelodysplasia

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMIFOSTINE; AMINOTHIOL; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AZACITIDINE; BEVACIZUMAB; CD34 ANTIGEN; CELL DNA; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; DNA METHYLTRANSFERASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; GLUTATHIONE; HISTONE DEACETYLASE INHIBITOR; LONAFARNIB; PENTOXIFYLLINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CLONE; CELL DIFFERENTIATION; CELL RENEWAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DNA METHYLATION; DOSE RESPONSE; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENE SILENCING; GENETIC ASSOCIATION; GLUTATHIONE METABOLISM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE RAS; OXIDATION; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0036219597     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_1-39     Document Type: Conference Paper

References (85)

1. Increasing incidence of myelodysplastic syndromes: Real or fictitious?
2. Myelodysplasia
3. Myelodysplastic syndromes in the elderly
4. Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases
5. The myelodysplastic syndromes: Biology and implications for management
6. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors
7. The myelodysplastic syndrome: Analysis of laboratory characteristics in relation to the FAB classification
8. Interleukin-6 and granulocyte-macrophage colony- stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells
9. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand
10. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome
11. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis
12. + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro
13. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death
14. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome
15. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia
16. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival
17. Ineffective erythropoiesis in myelodysplastic syndromes: Correlation with Fas expression but not with lack of erythropoietin receptor signal transduction
18. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
19. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
20. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes
21. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
22. + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration
23. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
24. Angiogenesis in myelodysplastic syndromes
25. Vascular endothelial growth factor is a secreted angiogenic mitogen
26. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
27. Proteolytic remodeling of extracellular matrix
28. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
29. KDR receptor: A key marker defining hematopoietic stem cells
30. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
31. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
32. Metalloproteinase-mediated release of human Fas ligand
33. Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis
34. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
35. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor
36. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
37. INK4b gene in myelodysplastic syndromes
38. INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression
39. Proposals for the classification of the myelodysplastic syndromes
40. Proposals for the classification of the acute leukaemias
41. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
42. Myelodysplastic syndromes: Introduction
43. Problematic WHO reclassification of myelodysplastic syndromes
44. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients
45. International scoring system for evaluating prognosis in myelodysplastic syndromes
46. Treatment of adult myelodysplastic syndromes
47. Advances in supportive care of myelodysplastic syndromes
48. Effects of three new recombinant, human GM-CSF/erythropoietin (EPO) hybrid molecules on in vitro growth of hemopoietic progenitors in myelodysplastic syndromes (MDS)
49. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia
50. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes
51. Randomized 3-armed phase III study of interleukin 3 (IL-3), or granulocyte/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-ARAC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS)
52. DNA methylation
53. DNA methylation: Past, present and future directions
54. A randomized controlled trial of subcutaneous azacitidine (AZA C) in patients with the myelodysplastic syndrome (MDS): A study of the cancer and leukemia group B (CALGB)
55. The impact of 5-azacytidine on the quality of life of patients with the myelodysplastic syndrome (MDS) treated in a randomized phase III trial of the cancer and leukemia group B (CALGB)
56. The potential of amifostine: From cytoprotectant to therapeutic agent
57. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity
58. Novel therapeutic agents for the treatment of myelodysplastic syndromes
59. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
60. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
61. Poor response rate to a continuous schedule of Amifostine therapy for 'low/ intermediate risk' myelodysplastic patients
62. Treatment of patients with myelodysplastic syndrome with amifostine
63. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
64. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
65. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
66. A new combination chemotherapy using topotecan, fludarabine, ARA-C and G-CSF for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly: Dose finding for topotecan study
67. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
68. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
69. Ras protein famesyltransferase: A strategic target for anticancer therapeutic development
70. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
71. Current status of clinical trials of farnesyltransferase inhibitors
72. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome
73. Phase II study of RI 15777, a farnesyltransferase inhibitor, in myelodysplastic syndrome
74. Angiogenesis in myelodysplastic syndromes
75. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
76. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
77. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
78. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
79. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
80. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
81. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
82. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
83. Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)
84. Report of an international working group to standardize response criteria for myelodysplastic syndromes
85. The molecular basis of myelodysplastic syndromes